Conjugate Vaccines Market Projected at $18.47 Billion by 2028, Driven by Major Advances in Preventive Healthcare and Technology

Dublin, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The "Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F" report has been added to's offering.

The global landscape of healthcare is witnessing a paradigm shift with the rising prominence of the Conjugate Vaccine Market, emerging as a significant player within the pharmaceutical sector. Analytical insights reveal the market's strong growth trajectory, projected to exhibit a compound annual growth rate (CAGR) of 7.23% from 2018 to 2028.

In light of heightened awareness towards preventive healthcare, conjugate vaccines have gained substantial market traction. These vaccines, known for their enhanced immunogenicity, are increasingly recognized as vital in preventing infectious diseases across numerous demographics.

More so, technological innovations have been instrumental in sculpting the Conjugate Vaccine Market's landscape. The advent of new vaccine production methodologies and enhanced adjuvants have not only bolstered the efficacy but also the safety of vaccines, catalyzing market expansion.

The urgency induced by infectious diseases, particularly underlined by the COVID-19 pandemic, remains a driving force behind the market's growth. This scenario has galvanized significant investments and innovation in vaccine research and development, reinforcing the conjugate vaccine infrastructure on a global scale.

The comprehensive coverage of pneumococcal diseases, Haemophilus influenzae type b infections, and meningococcal diseases, has resulted in the elevated demand for conjugate vaccines, establishing them as integral components of immunization programs universally.

Key market dynamics include:

  • Renewed focus on pediatric and geriatric vaccination strategies, where conjugate vaccines play a vital role in the prevention of diseases among these susceptible age groups.
  • Novel vaccine developments and scientific strides in biotechnology that foster the design of next-generation conjugate vaccines targeting emerging and existing infectious diseases.
  • Global efforts to combat antibiotic-resistant bacteria and the growing emphasis on alternative preventive methods like vaccination.

Regional analysis discloses North America as the dominant market, steered by its advanced healthcare infrastructure and high healthcare expenditure which contribute to extensive vaccine accessibility and innovation-driven growth.

Reflecting on product types and disease indications, multivalent conjugate vaccines and the pneumococcal segment are identified as leading market segments, catering to a broad patient demographic necessitating expansive immunization coverage.

Key Attributes

Report AttributeDetails
No. of Pages185
Forecast Period2023-2028
Estimated Market Value (USD) in 2023$12.24 Billion
Forecasted Market Value (USD) by 2028$18.47 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal

A selection of companies mentioned in this report includes:

  • Sanofi SA
  • Pfizer Inc.
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Bharat Biotech International Limited
  • Serum Institute of India Pvt. Ltd.
  • Biological E. Limited
  • Bavarian Nordic A/S
  • CSL Limited
  • Novartis AG

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Global Conjugate Vaccine Market

Contact Data